The implantable cardioverter-defibrillator: does everybody need one?

Area of Science:

• Cardiology
• Medical Devices
• Health Economics

Background:

• The implantable cardioverter-defibrillator (ICD) is an established treatment for preventing arrhythmic sudden cardiac death.
• ICD utilization is growing annually by 20% to 30%.
• Clinical trials confirm ICD efficacy in primary and secondary prevention for specific patient groups.

Purpose of the Study:

• To address unresolved issues concerning ICD therapy.
• To explore considerations beyond established clinical trial evidence.

Main Methods:

• Discussion of unresolved issues pertaining to ICD use.
• Analysis of patient populations not included in clinical trials.
• Review of factors influencing ICD selection and long-term outcomes.

Main Results:

• Identified key unresolved issues: patient selection, duration of benefit, quality of life, cost-effectiveness, and cost impact.
• Highlighted the need to consider patients outside of clinical trial parameters.
• Acknowledged the increasing trend in ICD adoption.

Conclusions:

• Despite proven efficacy, several critical aspects of ICD therapy require further investigation and resolution.
• Optimal patient selection, long-term outcomes, and economic evaluations are essential for comprehensive ICD implementation.